Not all Patients with Severe/Critical COVID-19 Pneumonia Benefit from Tocilizumab
DOI:
https://doi.org/10.51253/pafmj.v75i4.8053Keywords:
COVID-19, Inflammation, Mortality, Pneumonia SARS-CoV-2, Tocilizumab.Abstract
Objective: To determine serum IL-6 levels predictive of death during hospitalization for severe COVID-19 pneumonia, to rationalize treatment in resource-limited settings.
Study Design: Prospective longitudinal study.
Place and Duration of Study: Combined Military Hospital, Peshawar Pakistan from Aug to Sep 2021.
Methodology: Patients with severe COVID-19 pneumonia, confirmed by a positive SARS-CoV-2 polymerase chain reaction, who received Tocilizumab between August 2020 and July 2021 were included. Patients with negative polymerase chain reaction for SARS-CoV-2, incomplete data, and those admitted before August 2020 were excluded. Paper medical records of eligible patients were scrutinized to record serum C-reactive protein, ferritin, procalcitonin, and interleukin-6 levels within the 24 hours preceding Tocilizumab administration (one or two doses left at the discretion of the treating physician). In-hospital mortality or discharge status was also noted.
Results: Out of 88 patients aged 59.21±14.10 years, 54(61.36%) were males. Twenty-five (28.41%) patients died in the hospital. Area under ROC curve for mortality associated with interleukin-6 levels was 0.719(95% confidence interval 0.603, 0.836; p=0.001). Serum interleukin-6 levels ≥60.28 pg/ml or greater had a sensitivity of 68.00% and specificity of 63.49% for predicting death in hospital. Two doses of Tocilizumab were required in 78(88.64%) patients, and the mortality rate was not different from those receiving only one dose.
Conclusion: Tocilizumab should preferably be avoided in patients with serum interleukin-6 levels ≥10 times the normal.
Downloads
References
1. World Health Organization. WHO COVID-19 dashboard. WHO Health Emergencies Programme. [Internet]. Available at: https://covid19.who.int/ (Accessed on October 10, 2021)
2. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 2021; 97(1147): 312-320.
https://doi.org/10.1136/postgradmedj-2020-138577
3. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384(8): 693-704.
https://doi.org/10.1056/NEJMoa2021436
4. Ho KS, Narasimhan B, Difabrizio L, Rogers L, Bose S, Li L, et al. Impact of corticosteroids in hospitalised COVID-19 patients. BMJ Open Respir Res 2021; 8(1): e000766.
https://doi.org/10.1136/bmjresp-2020-000766
5. Wei Q, Lin H, Wei RG, Chen N, He F, Zou DH, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty 2021; 10(1): 71.
https://doi.org/10.1186/s40249-021-00857-w
6. Mussini C, Cozzi-Lepri A, Menozzi M, Meschiari M, Franceschini E, Milic J, et al. Development and validation of a prediction model for Tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One 2021; 16(2): e0247275. https://doi.org/10.1371/journal.pone.0247275
7. Arshad AR, Khan I, Shahzad K, Arshad M, Haider SJ, Aslam MJ. Association of inflammatory markers with mortality in COVID-19 infection. J Coll Physicians Surg Pak 2020; 30(10): 158-163.
https://doi.org/10.29271/jcpsp.2020.supp2.S158
8. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med 2020; 18(1): 406. https://doi.org/10.1186/s12967-020-02571-x
9. Guirao JJ, Cabrera CM, Jiménez N, Rincón L, Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Mol Immunol 2020; 128: 64-68.
https://doi.org/10.1016/j.molimm.2020.10.006
10. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. PLoS One 2020; 15(12): e0244628.
https://doi.org/10.1371/journal.pone.0244628
11. Rubio-Rivas M, Forero CG, Mora-Luján JM, Montero A, Formiga F, Homs NA, et al. Beneficial and harmful outcomes of Tocilizumab in severe COVID-19: A systematic review and meta-analysis. Pharmacotherapy 2021; 41(11): 884-906.
https://doi.org/10.1002/phar.2627
12. US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Actemra® (Tocilizumab). Genentech, Inc. [Internet]. Available at: https://www.fda.gov/media/150320/download (Accessed on October 10, 2021)
13. Mushtaq MZ, Mahmood SBZ, Jamil B, Aziz A, Ali SA. Outcome of COVID-19 patients with use of Tocilizumab : A single center experience. Int Immunopharmacol 2020; 88: 106926.
https://doi.org/10.1016/j.intimp.2020.106926
14. Amin S, Rahim F, Bahadur S, Noor M, Mahmood A, Gul H et al. The effect of Tocilizumab on inflammatory markers in survivors and non-survivors of severe COVID-19. J Coll Physicians Surg Pak 2021; 31(1): S7-S10.
https://doi.org/10.29271/jcpsp.2021.Supp1.S7
15. Hassan M, Syed F, Zafar M, Iqbal M, Khan NU, Mushtaq HF, et al. Tocilizumab and cytokine release syndrome in COVID-19 pneumonia: experience from a single center in Pakistan. Cureus 2021; 13(12): e20219.
https://doi.org/10.7759/cureus.20219
16. Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, et al; NIH COVID-19 Treatment Guidelines Panel. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Ann Intern Med 2024; 177(11): 1547-1557.
https://doi.org/10.7326/ANNALS-24-00464
17. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021; 384(16): 1491-1502.
https://doi.org/10.1056/NEJMoa2100433
18. Iftimie S, López-Azcona AF, Vallverdú I, Hernández-Flix S, de Febrer G, Parra S, et al. First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. PLoS One 2021; 16(3): e0248029.
https://doi.org/10.1371/journal.pone.0248029
19. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill 2021; 26(50): 2101147.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Abdul Rehman Arshad, Bilal Saeed, Imran Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
